Zenith Health Care Ltd
Incorporated in 1993, Zenith Health
care Ltd is engaged in manufacturing
and trading of pharma products[1]
- Market Cap ₹ 16.8 Cr.
- Current Price ₹ 3.12
- High / Low ₹ 4.99 / 2.23
- Stock P/E 1,677
- Book Value ₹ 1.38
- Dividend Yield 0.00 %
- ROCE 0.27 %
- ROE 0.13 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -5.20% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 1.22% over last 3 years.
- Working capital days have increased from 84.1 days to 122 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | 10.52 | |
| 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.23 | 11.24 | 10.65 | |
| Operating Profit | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.24 | 0.09 | -0.13 |
| OPM % | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.66% | 0.79% | -1.24% |
| 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.26 | 0.43 | 0.41 | |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 | 0.26 |
| Profit before tax | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 | 0.01 |
| Tax % | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% | 200.00% |
| -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | 0.01 | |
| EPS in Rs | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -53% |
| 3 Years: | -50% |
| TTM: | -83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -20% |
| 3 Years: | -8% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Reserves | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 | 2.05 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.56 | 3.48 | 3.57 | |
| Total Liabilities | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.99 |
| 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | 1.45 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.49 | 9.33 | 9.53 | |
| Total Assets | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.99 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.67 | -0.83 | |
| -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -1.88 | -1.09 | 0.85 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | |
| Net Cash Flow | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | -0.14 | -0.41 | 0.01 |
| Free Cash Flow | -0.18 | 0.11 | 0.11 | 0.00 | -0.11 | 1.45 | -1.66 | 1.08 | -0.95 | 1.63 | 0.28 | -0.99 |
| CFO/OP | -475% | -100% | 383% | 0% | -15% | 356% | -372% | 333% | -2,967% | 796% | 800% | 615% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 57.26 | 77.96 | 72.51 |
| Inventory Days | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 86.65 | 152.87 | 219.75 |
| Days Payable | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 38.08 | 91.59 | 112.89 |
| Cash Conversion Cycle | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 105.84 | 139.24 | 179.38 |
| Working Capital Days | 246.68 | 208.87 | 136.40 | 82.13 | 96.17 | 48.14 | 98.02 | 50.93 | 116.76 | 60.54 | 69.59 | 122.13 |
| ROCE % | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.12% | 0.27% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Sales INR Lakhs |
|
||||||||||
| Export Sales INR Lakhs |
|||||||||||
| Net Block (Property, Plant and Equipment) INR Lakhs |
|||||||||||
| Trade Receivable Turnover Ratio times |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Paper Cuttings of Published Audited Financial Result for the Quarter and year ended 31st March, 2026
-
Appointment Of Internal Auditor
29 May - Board appointed Tanaykumar Mohta as internal auditor for FY2026-27 on 29 May 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Akshit M. Raycha appointed Joint Managing Director for FY2026-27; term till next AGM, remuneration up to Rs. 24 lakh.
-
Standalone Audited Financial Result For The Quarter And Year Ended On 31.03.2026
29 May - Board approved FY26 audited results and appointed Akshit M. Raycha Joint Managing Director for 3 years.
-
Board Meeting Outcome for Outcome Of Board Meeting
29 May - Board approved FY26 audited results, appointed JMD and internal auditor, and noted related-party transactions.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
ZHL is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms.
The services include purchasing of raw materials, production, packaging, and quality control, and offering solid dosage forms in General and Beta-Lactam Tablets, Capsules, Oral Liquids, and Dry Powder Oral Suspension.